

Cytopathology CC Exam Module Study Guide

Registrants for the CY only or combined Primary/CY CC exam have only a single 150-question CY module. The module's topic list extends across both page 1 & 2.

CC CYTO - 150-Q Module	
• adrenal FNA; benign neoplasms	• LBCC; uterine malignant neoplasms
• adrenocortical carcinoma; IHC	• LBCC=liquid based cervical cytology
• amyloid	• liver FNA; malignant neoplasms; IHC
• anal cytology; LSIL	• liver FNA; metastatic germ cell tumor
• angiosarcoma; IHC	• liver FNA; metastatic neoplasms
• ASCCP cervical cancer screening guidelines	• liver FNA; reactive and benign disorders
• ASCCP guidelines; positive HPV with negative Pap	• LSIL; HPV cytopathic changes
• ASCCP management guidelines	• LSIL; HPV testing
• ASCCP recommendations; unsatisfactory specimen	• lung cancer; EGFR testing; mutations; resistance
• BAL; foreign material	• lung cancer; EML4/ALK
• BAL; lipid-laden macrophages	• lung FNA; false positive diagnoses
• BAL; reactive cells	• lung FNA; fungal organisms
• BAL; viral infections	• lung FNA; hamartoma
• Bethesda system; specimen adequacy	• lung FNA; lymphoma; immunophenotypes
• bevacizumab; adverse effects in lung cancer	• lung FNA; malignant neoplasms
• bile duct brush; reactive/reparative changes	• lung FNA; metastatic
• bone FNA; normal cells	• lymph node FNA; anaplastic large cell lymphoma
• breast FNA; benign lesions/neoplasms	• lymph node FNA; benign changes
• breast FNA; benign; inflammatory	• lymph node FNA; Hodgkin lymphoma
• breast FNA; ductal carcinoma variants	• lymph node FNA; inflammatory/infectious
• breast FNA; malignant	• lymph node FNA; metastatic carcinoma
• bronchial brush; pneumonia	• mediastinum FNA; granulomatous inflammation
• bronchial wash; Aspergillus	• medulloblastoma
• bronchial wash; malignant neoplasms	• Merkel cell carcinoma
• cholangiocarcinoma	• mesothelioma; IHC
• chylothorax	• metastatic papillary carcinoma of thyroid; ancillary testing
• CLIA amended reports	• NCI guidelines; benign thyroid FNA management
• CLIA cytology workload limits	• NCI guidelines; nondiagnostic thyroid aspirate
• CLIA GYN cyto/histo correlation	• pancreas EUS FNA, normal cells
• CLIA GYN lookback; diagnostic discrepancy	• pancreas FNA; cystic lesions
• CLIA slide count	• pancreas FNA; endocrine neoplasms; IHC
• CLIA; anorectal cytology	• pancreas FNA; malignant neoplasms
• CLIA; federal agency	• pancreas FNA; malignant neoplasms; IHC
• CNS neoplasms; non-glial	• pancreas FNA; mucinous neoplasms.
• CSF; malignant	• pancreatic mucinous cysts; Dx of malignancy
• CSF; metastatic carcinoma	• pelvic washings; benign cells
• CSF; neural tumors	• pericardial fluid; reactive/inflammatory cells

Cytopathology CC Exam Module Study Guide

• CSF; normal cells	• peritoneal fluid; benign cells
• cytology glass slide retention times	• peritoneal fluid; malignant cells; metastatic carcinoma
• EBUS-guided transbronchial FNA; advantages	• pheochromocytoma
• esophageal brush; metaplasia	• plasma cell myeloma
• extrarenal rhabdoid tumor	• pleura; mesothelium
• eye FNA	• pleural effusion; eosinophilic
• FDA approved HPV vaccines	• pleural fluid; leukemia/lymphoma
• germ cell tumors	• pleural fluid; malignant neoplasms; IHC
• Herpes	• pleural fluid; metastatic neoplasms
• high grade urothelial carcinoma; chromosomal abnormalities	• pleural fluid; sarcomas
• HPV gene activation	• polyoma virus
• HPV target amplification test methods	• retroperitoneal FNA; malignant mesenchymal neoplasms
• HSIL	• salivary gland FNA; benign cells
• HSIL; HPV testing	• salivary gland FNA; benign neoplasms
• HSIL; management	• salivary gland FNA; malignant neoplasms
• ICD-9/10 codes	• sensitivity, specificity; predictive value
• interobserver reproducibility on gyn cytology	• serous cystadenocarcinoma; metastatic
• IHC to distinguish thyroid from parathyroid tissue	• skin FNA; benign neoplasms
• Joint Commission; OPPE, FPPE	• skin FNA; malignant neoplasms
• kidney FNA; benign and malignant neoplasms	• soft tissue FNA; chordoma
• LBCC; adenocarcinoma in situ	• soft tissue FNA; benign/reactive lesions
• LBCC; adenocarcinoma, NOS	• soft tissue FNA; sarcomas; IHC; cytogenetics
• LBCC; ASCCP recommendations; unsatisfactory specimen	• specimen labeling
• LBCC adequacy	• sputum; benign cells
• LBCC; atrophy	• synovial fluid crystals
• LBCC; atypical endometrial cells	• thyroid FNA; benign
• LBCC; benign cell changes; granulomatous inflammation	• thyroid FNA; malignant neoplasms
• LBCC; benign changes; inflammation	• urine cytology; artifacts
• LBCC: cyto-histology correlation	• urine cytology; degenerative changes
• LBCC; direct extension of an adjacent malignancy	• urine cytology; hematuria
• LBCC; endocervical adenocarcinoma	• urine cytology; malignant neoplasms
• LBCC; parasites	• urine cytology; normal cells
• LBCC; postpartum	• urine cytology; specimen collection
• LBCC; pregnancy	• urine cytology; ileal conduit
• LBCC; squamous cell carcinoma	• urothelial carcinoma; IHC
• LBCC; Trichomonas; vaginal flora	• UroVision FISH
• LBCC; unsatisfactory	•